title: Effects of oxcarbazepine on monoamines content in hippocampus and head and body shakes and sleep patterns in kainic acid-treated rats.
abstract: The aim of this work was to analyze the effect of oxcarbazepine (OXC) on sleep patterns, "head and body shakes" and monoamine neurotransmitters level in a model of kainic-induced seizures. Adult Wistar rats were administered kainic acid (KA), OXC or OXC + KA. A polysomnographic study showed that KA induced animals to stay awake for the whole initial 10 h. OXC administration 30 min prior to KA diminished the effect of KA on the sleep parameters. As a measure of the effects of the drug treatments on behavior, head and body shakes were visually recorded for 4 h after administration of KA, OXC + KA or saline. The presence of OXC diminished the shakes frequency. 4 h after drug application, the hippocampus was dissected out, and the content of monoamines was analyzed. The presence of OXC still more increased serotonin, 5-hidroxyindole acetic acid, dopamine, and homovanilic acid, induced by KA.
authors.affiliation: Departamento de Neurofisiología, Laboratorio de Neuroquímica, Instituto Nacional de Rehabilitación, SSA, Calz. México-Xochimilco 289 Col. Arenal de Guadalupe, Delegación Tlalpan, C.P. 14389 México City, Mexico. alfa1360@yahoo.com.mx
authors.forename: Alfonso
authors.initials: A
authors.lastname: Alfaro-Rodríguez
authors.forename: Rigoberto
authors.initials: R
authors.lastname: González-Piña
authors.forename: Antonio
authors.initials: A
authors.lastname: Bueno-Nava
authors.forename: Emilio
authors.initials: E
authors.lastname: Arch-Tirado
authors.forename: Alberto
authors.initials: A
authors.lastname: Ávila-Luna
authors.forename: Rebeca
authors.initials: R
authors.lastname: Uribe-Escamilla
authors.forename: Javier
authors.initials: J
authors.lastname: Vargas-Sánchez
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use; D002220:Carbamazepine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D006624:Hippocampus / Q000187:drug effects*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007608:Kainic Acid / Q000009:adverse effects; D008297:Male; D000078330:Oxcarbazepine; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*; D012701:Serotonin / Q000378:metabolism*; D012894:Sleep Stages / Q000187:drug effects*
chemical_list: D000927:Anticonvulsants; D012701:Serotonin; D002220:Carbamazepine; D006897:Hydroxyindoleacetic Acid; D007608:Kainic Acid; D004298:Dopamine; D000078330:Oxcarbazepine; D006719:Homovanillic Acid